PyBOP
(Synonyms: 1H-苯并三唑-1-基氧三吡咯烷基六氟磷酸盐) 目录号 : GA11178
肽偶联剂
Cas No.:128625-52-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
IC50: Not available.
PyBOP (benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate), the analog of BOP where dimethylamino groups are replaced with pyrrolidino, is a peptide coupling reagent used in solid phase peptide synthesis. As the only analog of BOP which shows equivalent properties in peptide bond formation, PyBOP is widely used as a substitute for the BOP, with the aim of avoiding formation of hexamethylphosphoric triamide (HMPA) which is a carcinogenic side product. After being extensively reported with toxicity, HMPA has been recently included in the “Seveso list” of dangerous chemicals. Both in solution and in solid phase peptide synthesis, BOP performs as an excellent peptide coupling reagent. However, formation of HPMA couldn’t be avoided during the manufacture and utilization of BOP. [1]
In vitro: Under the same condition to that of BOP, coupling tests were conducted using PyBOP as coupling reagent. In the DCM molar solution containing N-protected amino acid, compounds were added as follow: coupling reagent, C-protected amino acid hydrochloride and DIEA. An immediate reaction could be then noticed by TLC monitoring, even in the case of hindered amino acids. Moreover, the magnitude of racemization seemed to be 50% lower than that obtained with BOP in the Young’s test, and exhibited superiority in the Anteunis’ test. [1]
In vivo: So far, no in vivo data has been reported.
Clinical trial: So far, no clinical trial has been conducted.
Reference:
[1]Coste J, Le-Nguyen D and Castro B. PyBOP@: A new peptide coupling reagent devoid of toxic by-product. Tetrahedron Lett. 1990 Mar; 31(2): 205-8.
| Cas No. | 128625-52-5 | SDF | |
| 别名 | 1H-苯并三唑-1-基氧三吡咯烷基六氟磷酸盐 | ||
| 化学名 | benzotriazol-1-yloxy(tripyrrolidin-1-yl)phosphanium;hexafluorophosphate | ||
| Canonical SMILES | C1CCN(C1)[P+](N2CCCC2)(N3CCCC3)ON4C5=CC=CC=C5N=N4.F[P-](F)(F)(F)(F)F | ||
| 分子式 | C18H28F6N6OP2 | 分子量 | 520.4 |
| 溶解度 | ≥ 52mg/mL in DMSO | 储存条件 | Desiccate at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.9216 mL | 9.608 mL | 19.216 mL |
| 5 mM | 0.3843 mL | 1.9216 mL | 3.8432 mL |
| 10 mM | 0.1922 mL | 0.9608 mL | 1.9216 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet